share_log
Benzinga ·  May 9 08:21
The FDA Has Granted Investigational New Drug Clearance For Can-Fite Biopharma's Namodenoson, For Metabolic Dysfunction-Associated Steatohepatitis, Also Known As Non-alcoholic Steatohepatitis, For The Company's Ongoing Phase 2B Study
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment